← All trials
NCT06590961
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2024
- Primary completion
- Aug 31, 2027
- Completion date
- Aug 31, 2027
- First posted
- Sep 19, 2024
- Last posted
- Sep 19, 2024
- Enrollment
- 94
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Ubix Therapeutics, Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.